Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

During median follow-up of 30 months in dal-OUTCOMES trial (n=15,871), incident diabetes was reduced with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib compared with placebo (7.6 vs 9.7%, respectively, risk reduction 2.1%;HR 0.77, 95% CI 0.68–0.88; p<0.001)

Diabetes Care